Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPresbyterian Thrombophilia Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentPresbyterian Health PlanPolicy 7.11

    Genetic Testing: Hypercoagulability/Thrombophilia

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy 7.11 alerts

    Get alerted when Policy 7.11 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for germline Factor II (F2) and Factor V (F5) genetic testing, as well as non-coverage of MTHFR testing, repeat germline testing, and certain VTE risk-score testing for Commercial, Medicaid, and Medicare members, subject to the member-specific benefit plan and Schedule of Benefits.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyGenetic Testing: Hypercoagulability/Thrombophilia
    Policy CodePolicy 7.11
    Change TypeMaterial revision
    Effective DateN/A
    Last ReviewMar 25, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization through Pres Online for covered Factor II and Factor V genetic testing.
    SourceLink
    POLICY UPDATE CHANGES

    Added non-coverage language for CPT 0529U, a genome-wide SNP VTE risk score including F2 and F5 analysis.

    Clarified that repeat germline testing billed with CPT 81240 or 81241 more than once in a lifetime is non-covered for Commercial, Medicare, and Medicaid members.

    Moved the annual review of MTHFR non-coverage from MPM 36.0 into this policy.

    Clarified that Medicaid coverage for Factor II and Factor V testing follows CMS/Novitas LCD guidance.

    2Covered hereditary mutation tests
    3Lines of business addressed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Once per lifetime
    Covered testing frequency
    3Non-covered or investigational categories
    RequiredAuthorization requirement

    Coverage Criteria

    Commercial Factor II and Factor V Testing

    For Commercial members, Factor II and Factor V germline testing is covered when performed to evaluate venous thromboembolism and the applicable MCG criteria are met.

    ONE of the following tests

    • Factor II (F2 gene) testing (CPT 81240), meeting MCG criterion A-0613.
    • Factor V (F5 gene) testing (CPT 81241), meeting MCG criterion A-0600.

    Medicare and Medicaid Factor II and Factor V Testing

    For Medicare and Medicaid members, Factor II and Factor V germline testing is covered when performed to evaluate venous thromboembolism and the applicable CMS/Novitas criteria are met.

    ONE of the following tests

    • Factor II (F2 gene) testing (CPT 81240), meeting CMS/Novitas Biomarkers Overview LCD L35062 and related article A56541.
    • Factor V (F5 gene) testing (CPT 81241), meeting CMS/Novitas Biomarkers Overview LCD L35062 and related article A56541.

    Medicare Symptomatic Presentation Limitation

    For Medicare, coverage applies only when the patient has signs and symptoms of disease.

    ALL of the following

    • The patient has signs and symptoms of disease.
    • The testing is not solely an assessment of thrombosis risk in an asymptomatic patient, including screening for inherited thrombophilia.
    • The testing is not performed solely because an asymptomatic individual has a relative with documented inherited thrombophilia.

    Repeat Germline Testing Limitation

    For Commercial, Medicare, and Medicaid members, repeat germline testing is non-covered when performed more than once in a lifetime.

    ALL of the following

    • The testing is germline testing, which seeks inherited variants or alleles present in all of the patient's cells and comprising the individual's baseline genetic code.

      Germline testing is differentiated from somatic testing, which identifies alterations specific to an individual cell or group of cells, such as a neoplasm or clonal hematopoietic cells.

    • The test is Factor II (CPT 81240) or Factor V (CPT 81241) testing.
    • The test has been performed more than once in the patient's lifetime.

      PHP follows WPS LCD L38429, Repeat Germline Testing.

    Testing for inherited thrombophilia in individuals who have experienced recurrent fetal loss or placental abruption is not covered because it is unclear whether anticoagulation therapy reduces recurrence.

    For Medicare, there is no benefit for assessment of thrombosis risk in asymptomatic patients, including screening for inherited thrombophilia, or for testing asymptomatic individuals solely because their relatives have documented inherited thrombophilia.

    Hematology (venous thromboembolism [VTE]) genome-wide single-nucleotide polymorphism variants, including F2 and F5 gene analysis and the Leiden variant, by microarray analysis of saliva and reported as a VTE risk score (CPT 0529U), is not medically necessary and is not covered. The test lacks sufficient analytical validation, clinical utility, and clinical validation to demonstrate its accuracy, reliability, and usefulness in guiding clinical decision-making.

    Coding and Frequency Limits

    Covered CPT CodesCPTCovered
    81240F2 (prothrombin, coagulation factor II) (eg, hereditary hypercoagulability) gene analysis, 20210G>A variant.
    81241F5 (coagulation factor V) (eg, hereditary hypercoagulability) gene analysis, Leiden variant.
    Experimental CPT CodesCPTExperimental
    81291MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C).
    Not Covered CPT CodesCPTNot Covered
    0529UHematology (venous thromboembolism [VTE]), genome-wide single-nucleotide polymorphism variants, including F2 and F5 gene analysis, Leiden variant, by microarray analysis, saliva, report as risk score for VTE.
    Repeat Germline Testing
    Applies toCommercial, Medicare, and Medicaid members
    Applicable codesCPT 81240 and 81241
    Coverage limitRepeat germline testing more than once in a lifetime is non-covered

    Provider Actions and Billing Requirements

    Prior Authorization

    Prior Authorization Required for F2 and F5 Testing

    Prior authorization is required for Factor II (F2) and Factor V (F5) testing. Submit the request through Pres Online: https://ds.phs.org/preslogin/index.jsp.

    • Applies to CPT 81240 (F2/prothrombin) and 81241 (F5/Factor V Leiden).
    • Continue current configuration requiring prior authorization unless billed by a Hematology/Oncology provider.
    Documentation Required

    Authorization and Supporting Records

    Submit the required authorization and maintain documentation supporting the applicable coverage criteria. Providers must maintain or have access to supporting records when PHP requests them.

    • Retain clinical documentation supporting the indication and medical necessity.
    • Consult the applicable MCG criteria, Medicare/Medicaid LCDs and articles, and related policy references.

    Clinical Background

    Factor V Leiden thrombophilia is an inherited F5 disorder that causes resistance to activated protein C and predisposes individuals to venous thromboembolism. Factor II prothrombin thrombophilia is the second most common genetic risk factor for venous thromboembolism after Factor V Leiden.

    Definitions

    Germline Testing
    Test typeTesting that identifies inherited variants or alleles
    DistributionThe variants are present in all of the patient's cells
    Genetic significanceThe variants make up the individual's baseline genetic code
    Factor V Leiden Thrombophilia
    Genetic basisAn inherited disorder of the F5 gene
    MechanismResults in resistance to activated protein C
    Clinical riskPredisposes patients to venous thromboembolism

    Covered Indications

    Evaluation of Venous Thromboembolism Using Germline Factor II or Factor V Testing

    Covered when the applicable plan-specific criteria are met:

    Covered indication: Evaluation of venous thromboembolism using germline Factor II (F2) or Factor V (F5) hereditary mutation testing.

    Commercial coverage is subject to applicable MCG criteria; Medicare and Medicaid coverage is subject to applicable CMS/Novitas criteria.

    Eligibility Requirements

    For Medicare, an asymptomatic individual whose relative has documented inherited thrombophilia is not eligible for coverage solely for thrombosis-risk assessment. Medicare coverage applies only when the individual has signs and symptoms of disease.

    Not Covered Services

    The following testing is not covered: MTHFR genotyping (**CPT 81291**) for any clinical scenario; repeat germline Factor II (**CPT 81240**) or Factor V (**CPT 81241**) testing more than once per lifetime; inherited thrombophilia testing for recurrent fetal loss or placental abruption; and genome-wide VTE risk-score testing (**CPT 0529U**).

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyGenetic Testing: Hypercoagulability/Thrombophilia
    Policy CodePolicy 7.11
    Change TypeMaterial revision
    Effective DateN/A
    Last ReviewMar 25, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization through Pres Online for covered Factor II and Factor V genetic testing.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Frequency LimitsProvider Actions and Billing RequirementsClinical BackgroundDefinitionsCovered IndicationsEligibility RequirementsNot Covered Services

    Unsupported block type: billing_rule

    Denial Risk

    Asymptomatic Thrombophilia Screening Not Covered

    Medicare coverage applies only to individuals with signs and symptoms of disease. Screening for inherited thrombophilia is not a Medicare benefit for asymptomatic patients, including asymptomatic individuals whose relatives have documented inherited thrombophilia.

    • Do not submit Factor II or Factor V testing for assessment of thrombosis risk in an asymptomatic Medicare patient.
    • Family history of inherited thrombophilia alone does not establish a Medicare-covered indication.
    Denial Risk

    Repeat Germline Testing Is Non-Covered

    For Commercial, Medicare, and Medicaid members, repeat germline testing for Factor II or Factor V more than once in a lifetime is non-covered.

    • CPT 81240 and 81241 are subject to the once-per-lifetime limitation.
    • Germline testing identifies inherited variants present in the patient’s baseline genetic code; this limitation is distinct from testing for somatic alterations.
    Denial Risk

    MTHFR Testing Is Investigational and Non-Covered

    MTHFR genotyping has no established clinical utility in any clinical scenario and is considered investigational. It is not a Medicare, Commercial, or Medicaid benefit.

    • CPT 81291 (MTHFR common-variant analysis) is non-covered for all lines of business.
    • Configure and process CPT 81291 as investigational/experimental.
    Denial Risk

    Genome-Wide VTE Risk Scoring Is Not Covered

    Genome-wide single-nucleotide polymorphism testing reported as a venous thromboembolism risk score is not covered because it is not medically necessary and lacks sufficient analytical validation, clinical utility, and clinical validation.

    • CPT 0529U includes genome-wide VTE risk-score testing involving F2 and F5 variants, including Leiden variant analysis.
    • Configure CPT 0529U as investigational/experimental; a once-per-lifetime limitation is not required for a code classified as investigational and experimental.
    Denial Risk

    Recurrent Fetal Loss or Placental Abruption

    Inherited thrombophilia testing is not covered when performed for recurrent fetal loss or placental abruption because it is unclear whether anticoagulation therapy reduces recurrence.

    • Apply this non-coverage limitation to Commercial, Medicare, and Medicaid members.
    • Do not use recurrent fetal loss or placental abruption alone as a covered indication for inherited thrombophilia testing.
    Note

    Provider Actions and Current Policy Guidance

    Use the current policy criteria and configuration when requesting or adjudicating F2, F5, MTHFR, and genome-wide VTE risk-score testing. For coverage determinations, providers are expected to maintain access to the applicable source documentation and current referenced guidelines.

    • F2 and F5: follow the applicable MCG criteria for Commercial members and Novitas LCD/article guidance for Medicare and Medicaid members.
    • MTHFR: follow the applicable MCG and WPS LCD/article guidance for non-coverage.
    • Review the policy references and publication history for current requirements before submitting claims or authorization requests.
    Factor II Prothrombin Thrombophilia
    ConditionFactor II prothrombin thrombophilia
    Genetic significanceThe second most common genetic risk factor for venous thromboembolism
    Relative frequencyOccurs after Factor V Leiden thrombophilia in frequency among genetic VTE risk factors